Ampligene India Biotech Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 12 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 224.01%
- Profit Growth 45.06%
- Ebitda 689.36%
- Net Worth 46.01%
- Total Assets -0.84%
About Ampligene India Biotech
Ampligene India Biotech Private Limited (AIBPL) is a Private Limited Indian Non-Government Company incorporated in India on 18 September 2012 and has a history of 12 years and five months. Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Machinery And Equipment Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Nirupama Pandya, Deepal Pandya, and Chirag Pandya serve as directors at the Company.
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U52100GJ2012PTC072019
- Company No.
072019
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Sep 2012
- Date of AGM
20 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Ampligene India Biotech?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Deepal Pandya  | Director | 08-Dec-2012 | Current |
| Nirupama Pandya | Director | 18-Sep-2012 | Current |
| Chirag Pandya | Director | 17-Jul-2018 | Current |
Financial Performance of Ampligene India Biotech.
Ampligene India Biotech Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 224.01% increase. The company also saw a substantial improvement in profitability, with a 45.06% increase in profit. The company's net worth Soared by an impressive increase of 46.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ampligene India Biotech?
Unlock access to Ampligene India Biotech's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Ampligene Diagnostics Private LimitedDeepal Pandya and Chirag Pandya are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ampligene India Biotech?
Unlock and access historical data on people associated with Ampligene India Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ampligene India Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ampligene India Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
